Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 7/20 | 0.46 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11330348 | 0.78 | CA2 (0.67) | CA2CNR2CA1MCL1HPGD | |
| SCHEMBL10934176 | 0.74 | PTGS1 (0.64) | CA2CA1MCL1TSHRSLC22A12 | |
| SCHEMBL6001677 | 0.74 | CA2 (0.48) | CA2CNR2CA1SLC22A12PTGS1 | |
| SCHEMBL11133599 | 0.71 | CA2 (0.70) | CA2PTGES2CA1SLC22A12PTGS1 | |
| SCHEMBL2080151 | 0.71 | CA2 (0.45) | CA2CA1PTGS1PTGS2 | |
| SCHEMBL30697126 | 0.70 | HSD11B1 (0.59) | TSHRHSD11B1 | |
| SCHEMBL248010 | 0.70 | HSD11B1 (0.59) | TSHRHSD11B1 | |
| SCHEMBL2079574 | 0.70 | CA2 (0.49) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL2123876 | 0.70 | HSD11B1 (0.59) | TSHRHSD11B1 | |
| SCHEMBL1414850 | 0.70 | CA2 (0.72) | CA2PTGES2CA1SLC22A12PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | ELANE, CTRL, PIGO | CA2 3839/4885CNR2 1110/4885CNR1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.